Smoking cessation medicines does not raise serious cardiovascular event risk

Anuja Vaidya -

A study published in JAMA Internal Medicine examined whether smoking cessation treatments increases the risk of serious cardiovascular events.

Researchers conducted a double-blind, randomized trial and a nontreatment extension trial at 140 multinational centers. They studied 8,058 smokers who received at least 1 dose of study medication as well as a subset of 4,595 who completed 12 weeks of treatment and 12 weeks of follow up and agreed to be followed up for an additional 28 weeks.

The smoking cessation treatments included Varenicline, bupropion hydrochloride and nicotine replacement therapy.

The study shows a low incidence of cardiovascular events during treatment and follow-up and the risk of cardiovascular events did not differ significantly by treatment. Additionally, no significant treatment differences were observed in time to cardiovascular events, blood pressure or heart rate.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.